Heat Biologics (HTBX) Given News Impact Rating of 0.11
News articles about Heat Biologics (NASDAQ:HTBX) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heat Biologics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.7778043094806 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Heat Biologics (NASDAQ:HTBX) traded up $0.03 on Friday, hitting $2.03. 484,133 shares of the stock traded hands, compared to its average volume of 534,620. The company has a market cap of $8.53, a PE ratio of -0.49 and a beta of 0.78. Heat Biologics has a one year low of $1.90 and a one year high of $12.50.
Separately, ValuEngine cut shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.